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e.2011.11Abstract Background: CD44 is a polymorphic family of cell surface proteoglycans and glycopro-
teins implicated in cell-to-cell and cell-to-matrix adhesion interactions and tumor metastasis.
Aim: This study was designed to histopathologically examine and immunohistochemically detect
the expression of CD44v6 in differentiated thyroid carcinomas, and its association with clinicopath-
ologic parameters.
Methods: Forty different thyroid lesions constituted the material of this study. Cases were divided
into a malignant (n= 30) and a non-malignant group (n= 10). Immunostaining was manually per-
formed using CD44v6 mouse monoclonal antibody.
Results: CD44v6 expression was signiﬁcantly higher in malignant compared to non-malignant
lesions. This signiﬁcance was not maintained when cases were categorized as neoplastic and non-
neoplastic. Female sex and patients age <45 years were signiﬁcantly associated with higher
CD44v6 expression in the malignant group. Papillary thyroid carcinoma (PTC) showed higher
CD44v6 expression than follicular thyroid carcinoma (FTC). CD44v6 immunopositivity did not
signiﬁcantly associate with the microscopic variant of PTC and FTC. Also, tumor size failed tontiation 44; FFPE, formalin
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242 S.M. El-Gendi et al.relate signiﬁcantly with CD44v6 expression within the subtypes of PTC and FTC. However, female
sex, patient age <45 years, and tumor size between 1-4cms associated with signiﬁcantly higher
CD44v6 expression in the PTCs when compared to non-malignant lesions. In FTCs no signiﬁcant
relationship was observed between CD44v6 immunopositivity and patients’ age, sex, or tumor size.
In the non-malignant group no signiﬁcant relationship was found between CD44v6 immunopositiv-
ity and patients’ sex, or age. The background non-neoplastic thyroid tissue was CD44v6 negative in
all cases of both groups except for 4 cases of PTCs.
Conclusion: Deregulated expression of CD44v6 occurs in differentiated thyroid carcinomas and in
benign thyroid nodules. Thus, further studies are warranted to investigate the diagnostic utility of
CD44v6 expression in the differentiation of benign from malignant thyroid lesions. Also, the pre-
dictive value of CD44v6 deregulated expression in PTC and the occurrence of nodal metastasis
needs further veriﬁcation.
ª 2011 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Thyroid tumors are the most common malignancies of the
endocrine system.1 In Egypt thyroid cancer represents 1.2%
of cancers in males and 2.2% of cancers in females, and ranks
the 10th most common cancer site among females.2
CD44 is a polymorphic family of immunologically related
integral membrane glycoproteins and proteoglycans, impli-
cated in cell-cell and cell-matrix adhesion,3–6 lymphocyte acti-
vation and homing,7 cell migration, and tumor metastasis.3–7
CD44 is encoded by a gene located on 11p13 chromosome
and consists of at least 20 exons. Polypeptide isoforms of
CD44 are produced by alternative splicing of at least 10 of
the 20 exons during mRNA processing.7,8 The simplest
CD44 isoform (CD44 standard or CD44s) does not contain
any additional exon product and is expressed by hematopoietic
cells and most of the epithelial cells.7,9
Alternations in the composition of CD44 protein and of its
isoforms are associated with neoplastic transformation and
metastasis in a number of different tissues. So, increased expres-
sion of CD44 has been implicated in melanoma metastasis,7,10
pancreatic adenocarcinomas, colorectal carcinomas,7,11 non-
Hodgkin lymphomas, breast and lung carcinomas.7,12 On the
other side, decreased expression of CD44v6 is related to tumor
recurrence and unfavorable outcome in poorly differentiated
squamous cell carcinoma,7,12 laryngeal carcinomas, superﬁcial
bladder carcinoma7,13 and prostate carcinomas.7,14,15
CD44 variant isoforms are also expressed in normal and neo-
plastic thyroid tissues, but it is unclear whether they have any
prognostic value in differentiated thyroid carcinomas,7,14 which
include papillary and follicular carcinomas and their subtypes.7,8
The aim of this study was to histopathologically
examine and immunohistochemically detect the expression of
CD44v6 in papillary and follicular thyroid carcinomas, in
addition to evaluating the expression of CD44v6 in benign thy-
roid lesions to evaluate any possible alteration in its expres-
sion. Also we associated CD44v6 expression in the different
studied thyroid lesions with clinicopathologic parameters.
2. Methods
The present study included a total of 40 cases representing dif-
ferent thyroid lesions both neoplastic and non-neoplastic.
Clinical data including patients’ age, sex, clinical presentation,
and type of operation (total, subtotal or hemithyroidectomy)were obtained by reviewing the pathology request forms. The
study was approved by the Alexandria University, Faculty of
Medicine Research Ethics Committee.
One parafﬁn block representative of the lesion with ade-
quate material suitable for immunohistochemical (IHC) studies
was selected for every case. The formalin ﬁxed parafﬁn-embed-
ded (FFPE) tissue blocks were cut into 5 lm thick sections that
were reevaluated without the knowledge of any previous diag-
nosis. As a ﬁrst step, hematoxylin and eosin (H&E) stained sec-
tions were assessed to diagnose all cases. The presence of
background lesions e.g. Hashimoto’s thyroiditis in cases of
PTC or degenerative changes in cases of adenomas were noted.
2.1. Immunohistochemistry
Five micron-thick sections, of FFPE tissue blocks were cut and
mounted on coated slides. Tissue sections were deparafﬁnized in
standard xylene and rehydrated in a graded alcohol series
(100% to 70%) followed by incubation in Hydrogen Peroxide
Block for 10-15 minutes, to block the endogenous peroxidase
activity (EPA) to reduce nonspeciﬁc background staining. For
CD44v6 immunostaining heat induced antigen retrieval was
done in microwave oven using sodium citrate buffer (0.01 M
Na-citrate monohydrate, pH 6.0) for 10 min, then allowed to
cool down to room temperature. Tissue sections were immuno-
stained for CD44 using mouse monoclonal antibody, (CD44v6,
clone VFF-7 that speciﬁcally recognizes an epitope encoded by
exon v6 on the variant portion of human CD44) provided by
Bender Medsystems, Vienna, Austria diluted at 1:350 and incu-
bated overnight at 4 C in a humidiﬁed chamber. The antigen-
antibody reaction was visualized by Thermo scientiﬁc UltraVi-
sion LP Detection System. Immunohistochemical reactions
were developed with diaminobenzidine. Sections were counter-
stained with Harrris hematoxylin and covered by a coverslip
using Canada balsam. All immunostains were manually
processed with the utilization of appropriate positive and nega-
tive controls for each batch of slides.
2.2. Quantiﬁcation of immunostaining
The immunostained slides were then evaluated and scored by
two pathologists, independently without knowledge of any
clinical data. The percentage of positive cells was counted in
10 high power ﬁelds (HPF) using semiquantitative method:
0 = negative; 1+= less than 25% positive staining; 2+=
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area. The intensity of the stained cells was recorded as weak,
moderate or strong but was not scored. Only continuous mem-
branous immunoreactivity was considered positive. Neither
cytoplasmic staining alone nor punctate membrane staining
was considered positive.7
2.3. Statistical analysis of the data
Data were analyzed using SPSS software package version 18.0
(SPSS, Chicago, IL, USA).16 Quantitative data were expressed
using minimum, maximum, mean, standard deviation, median
and inter-quartile range as the distribution was abnormal. The
qualitative data were expressed in frequency and percent.
Qualitative data were analyzed using Chi-square test also exact
tests such as Fisher exact and Likelihood Ratio were applied to
compare groups. Quantitative data were analyzed using Mann
Whitney test to compare between any two groups. Spearman
correlation was used and regression equation was determined
if there was signiﬁcant correlation. Scatter plot was drawn to
present the correlation and regression. Agreement of the differ-
ent predictives with the outcome was used and expressed in
sensitivity, speciﬁcity, positive predictive value, negative pre-
dictive value, and accuracy of the CD44v6 where histomor-
phologic diagnosis was considered as the gold standard.
Sensitivity was deﬁned on the basis of thyroid cancer detection
using immunostaining for CD44v6 [no. positive/(true positi-
ve + false negative)]. Speciﬁcity was deﬁned on the basis of
benign thyroid lesions detection [no. negative/(true negative +
false positive)]. Positive and negative predictive values were
computed as no. positive/ (true positive + false positive) and
no. negative/true negative + false negative), respectively.
p-Value was assumed to be signiﬁcant at 0.05.
3. Results
3.1. Clinical data
The present study included 40 cases of different thyroid lesions
both neoplastic and non-neoplastic. The forty cases were di-
vided into two major groups: malignant and non-malignant.
Group 1 included 30 cases of papillary and follicular thyroid
carcinomas, whereas group 2 included 10 cases of different be-
nign thyroid lesions. The age of the patients ranged between 14
and 70 years (mean ± SD 44.18 ± 13.25 years). Nineteen
cases were < 45 years and 21 cases wereP 45 years. Six cases
were males (15%) and 34 cases (85%) were females.
3.2. Histopathological examination
Histopathological examination of the H&E stained sections re-
vealed 24 (60%) papillary thyroid carcinoma cases (PTC), 6
cases (15%) follicular thyroid carcinoma (FTC), 4 cases
(10%) multinodular colloid goiter, 3 cases (7.5%) adenoma
of the thyroid and 3 cases (7.5%) Hashimoto’s thyroiditis.
3.3. Group 1; Malignant cases (n = 30)
Twenty-four out of the 30 cases (80%) in this group were
females and 6 cases (20%) were males.3.4. Papillary thyroid carcinomas
Nineteen cases (79.2%) were females and 5 cases (20.8%) were
males. The patients’ age in thirteen cases (54.2%) was
<45 years and in 11 cases (45.8%) was P45 years.
The 24 PTC were microscopically subtyped according to De
Lellis et al.2 into: 8 cases (33.3%) conventional (or classic) type
of PTC, 6 cases (25%) micropapillary variant of PTC carci-
noma, 7 cases (29.2%) follicular variant of PTC (FVPTC), 2
cases (8.3%) encapsulated variant of PTC, and 1 case (4.2%)
tall or columnar cell variant of PTC.
A signiﬁcant relationship between the microscopic subtype
of PTC and tumor size was noted for tumors with diameter
<1 cm as well as for tumor size between 1 and 4 cms;
(p< 0.001 for both diameters). This signiﬁcant association
was not maintained for tumor size > 4 cm, (p= 0.091). With-
in the 24 PTC cases no signiﬁcant association was observed
between tumor size and patients’ age (p= 0.340), patients’
sex (p= 0.145), and TSH level (p= 0.422).
3.5. Follicular thyroid carcinoma
Five cases (83.3%) were females and one case (16.7%) was a
male. The age range was 38–62 years (mean ± SD
53.33 ± 8.82 years). The tumor size ranged from 1 to 3 cm
(mean ± SD 2.08 ± 0.80 cm).
The six cases of follicular thyroid carcinoma were
microscopically subtyped according to De Lellis et al.2 into:
two cases (33.3%) minimally invasive FTC and four cases
widely invasive FTC (66.7%); among these four cases a case
was diagnosed as Hu¨rthle cell carcinoma.
3.6. Group 2 (non-malignant cases)
All 10 cases in this group were females. Three cases were ade-
nomas (one microfollicular, one mixed micro and macrofollic-
ular and the third was a Hu¨rthle cell adenoma), three cases
were Hashimoto’s thyroiditis and four cases were multinodular
colloid goiters.
3.7. CD44v6 immunohistochemical staining of tissue sections
CD44v6 positive immunostaining revealed signiﬁcantly higher
expression in the malignant (80% of cases CD44v6 positive)
versus the non-malignant (30% of cases CD44v6 positive)
cases; (p= 0.006), Table 1. This statistical signiﬁcance was
not maintained when cases were categorized as neoplastic (dif-
ferentiated thyroid carcinomas, and adenoma cases) and non-
neoplastic.
Statistical analysis between both groups (groups 1 and 2)
indicated that female sex, patients’ age <45 years and thyroid
stimulating hormone (TSH) P1.8 uLU/ml were associated
with signiﬁcantly higher levels of CD44v6 immunopositivity
in malignant compared to non-malignant lesions; (p= 0.015,
p= 0.017, and p= 0.048, respectively).
The sensitivity and the speciﬁcity of CD44v6 positive
immunoreactivity in malignant versus non-malignant cases
were 80% and 70%, respectively. Positive and negative predic-
tive values were 88.89% and 53.85%, respectively.
Table 2 CD44v6 immunoreactivity in the different subtypes of PTC.
CD44v6 Total
0 1+ 2+ 3+
No. % No. % No. % No. % No. %
Conventional papillary thyroid carcinoma 0 0.0 2 8.3 3 12.5 3 12.5 8 33.3
Micro Papillary carcinoma of the thyroid 3 12.5 2 8.3 0 0.0 1 4.2 6 25.0
Follicular variant papillary thyroid carcinoma 1 4.2 0 0.0 2 8.3 4 16.7 7 29.2
Encapsulated papillary thyroid carcinoma 0 0.0 0 0.0 0 0.0 2 8.3 2 8.3
Papillary thyroid carcinoma columnar cell type 0 0.0 0 0.0 0 0.0 1 4.2 1 4.2
Total 4 16.7 4 16.7 5 20.8 11 45.8 24 100.0
MCp 0.464*
MCp: p value for Monte Carlo test.
* Statistically signiﬁcant at p 6 0.05
Table 1 CD44v6 immunoreactivity in the malignant and non-malignant cases.
CD44v6 Total FEp
ve +ve
No. % No. % No. %
Malignant 0.006*
Papillary carcinoma 4 16.7 20 3.3 24 100.0
Follicular carcinoma 2 33.3 4 66.7 6 100.0
Non-malignant lesion
Follicular adenoma 3 100.0 0 0.00 3 100.0
Hashimoto’s thyroiditis 2 66.7 1 33.3 3 100.0
Multi nodular goiter 2 50.0 2 50.0 4 100.0
FEp: p value for Fisher Exact test.
* Statistically signiﬁcant at p 6 0.05
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Twenty out of the 24 cases (83.3%) of PTC included in this
study stained positive for CD44v6. Eleven cases (45.8%)
showed membranous immunopositivity in >50% of tumor
cells population and were given score 3, 5 cases (20.8%)
showed immunopositivity in 20–50% of tumor cells popula-
tion and were given score 2, and the remaining 4 cases
(16.7%) showed positive staining in <25% of tumor cell pop-
ulation and were given score 1. Table 2 and Fig. 1 show the
CD44v6 immunoreactivity in the different subtypes of PTC.
The staining intensity varied between strong (14 cases;
58.4%), moderate (5 cases; 20.8%), and weak (5 cases;
20.8%). Also, intratumoral variability of staining intensity
was noted, and characteristically the strongest intensity was
seen at the tumor border and invasive edges.
Out of 24 cases of PTC; only nine cases were submitted with
cervical lymphadenectomy. Four out of those nine cases
(44.4%) showed nodal metastatic deposits that were also
immunostained using CD44v6 and revealed positive strong
and diffuse immunoreactivity in all four cases.
The background thyroid tissue showed positive CD44v6
immunoreactivity in four out of the 24 PTC cases, three
cases were score 2 with moderate to weak intensity (two
cases of conventional PTC, and one case of FVPTC), and
the fourth case (micropapillary variant of PTC) was score
1 with focal and weak immunostaining. The backgroundthyroid tissue was totally negative in the remaining 20
cases.
In the present study, papillary thyroid carcinoma showed
signiﬁcantly higher CD44v6 expression compared to non-
malignant lesions, (p= 0.005). CD44v6 immunopositivity
did not associate with PTC microscopic subtype,
(p= 0.147). Also, the extent of CD44v6 expression (score)
did not associate with PTC microscopic subtypes. CD44v6
immunopositivity within the different subtypes of PTC showed
a signiﬁcant association with patients’ age only for age group
P45 years; (p= 0.038), and not in the age group <45 years.
No statistically signiﬁcant relationship was found between
CD44v6 immunostaining and sex within the different subtypes
of PTC.
Statistical analysis showed that female sex, patients’ age
<45 years and tumor size ranging between 1 cm and 4 cm
were associated with signiﬁcantly higher levels of positive
CD44v6 immunostaining in PTC compared to non-malignant
lesions; (p= 0.011, p= 0.022 and p= 0.017, respectively).
There was a signiﬁcant positive and moderate correlation be-
tween CD44v6 immunostaining and the largest tumor size
(rho = 0.536, p= 0.007), and 31.4% of the changes in
CD44v6 could be explained by variations in the largest tumor
size as R2 = 0.314. The CD44v6 value could be predicted by
determining the largest tumor size according to the regression
equation as for each unit change in the largest tumor size the
CD44v6 increased by 0.515 (Fig. 2).
Figure 1 (A) Conventional (classic) PTC showing intense membranous immunopositivity, (CD44v6, ·400). (B) Follicular variant of
PTC showing follicles with strong membranous immunostaining, (CD44v6, ·200). (C) Encapsulated variant of PTC, score 3; with
capsular ﬁbroblast serving as positive internal control, (CD44v6, ·100). (D) Columnar cell variant of PTC, score 3, (CD44v6, ·100). (E)
Higher power of the previous case showing strong cytoplasmic membrane immunoreactivity (CD44v6, ·400).
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tion between CD44v6 and the smallest tumor size (rho =
0.633, p= 0.001), and 33.2% of changes in CD44v6 could
be explained by variations in the smallest tumor size as
R2 = 0.332. The CD44v6 value could be predicted by
determining the smallest tumor size according to regression
equation as for each unit change in the smallest tumor size
the CD44v6 increased by 0.714 (Fig. 3).
The sensitivity and the speciﬁcity of CD44v6 in papillary
thyroid carcinoma versus non-malignant lesions were 83.3%
and 70.0%, respectively. Positive and negative predictive val-
ues were 86.96% and 63.6%, respectively.
3.9. CD44v6 expression in follicular carcinoma cases
Four out of six FTC cases included in the present study
showed CD44v6 positive immunoreactivity. Three cases were
score 3 (one case minimally invasive FTC and two cases widelyinvasive FTC), and the fourth case was given score 1 (widely
invasive FTC), (Fig. 4).
The sensitivity and the speciﬁcity of CD44v6 positive
immunostaining in follicular thyroid carcinoma versus non-
malignant lesion were 66.67% and 70.00%, respectively. Posi-
tive and negative predictive values were 57.14% and 77.78%,
respectively.3.10. CD44v6 expression in the non- malignant group
In the non-malignant group CD44v6 positive immunostaining
was detected in only three out of 10 cases (30%). All three
cases of benign thyroid adenomas were CD44v6 negative,
Fig. (5A, 5B). Two out of 4 multinodular goiters and one
out of three Hashimoto’s thyroiditis showed CD44v6 immu-
nopositivity and were given scores 3, 2, and 1, respectively,
Fig. 5C and D, respectively).
Figure 2 Scatter plot for the relation between CD44v6 and
largest tumor size among papillary thyroid carcinoma cases.
Rho = 0.536*, p= 0.007; R= 0.561, R2 = 0.314 CD44v6 =
0.734 + 0.515 · largest tumor size t= 3.175*, p= 0.004.
Figure 3 Scatter plot for the relation between CD44v6 and
smallest tumor size among papillary thyroid carcinoma cases.
Rho = 0.633*, p= 0.001; R= 0.576, R2 = 0.332, CD44v6 =
0.619 + 0.714 · smallest tumor size, t= 3.304*, p= 0.003.
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tionship was found between CD44v6 immunopositivity and
patients’ age, patients’ sex, or TSH level.
4. Discussion
CD44 exists as a standard molecule and as multiple isoforms
(v1–v10).6,17–19 CD44v6 exists in proliferating thyroid cells,
and is upregulated in carcinomas.4,19 Several studies reported
that PTCs, adenomas and multinodular goiters exhibit an in-
crease in CD44 mRNA isoforms, that distinguish them from
the histologically normal thyroid tissue,4,7,8 while others con-
cluded that the majority of PTCs overexpress CD44 in contrastto normal follicular cells and non-papillary carcinoma thyroid
lesions.20,21 In differentiated thyroid carcinoma it is still un-
clear whether the deregulated expression of CD44 has any
prognostic value.7,14
The current study was undertaken to analyze CD44v6
expression in differentiated thyroid carcinomas and to corre-
late CD44v6 immunoreactivity to clinicopathological
parameters.
Although some studies reported CD44v6 to be a marker of
deregulated thyrocyte proliferation that is overexpressed in
proliferating benign and malignant thyroid lesions,7,22,23 yet
in agreement with Li et al.24 in this study CD44v6 expression
was signiﬁcantly higher in malignant compared to non-malig-
nant lesions. This statistical signiﬁcance was not maintained
when cases were categorized as neoplastic and non-neoplastic,
which implies that although CD44v6 is highly expressed in
neoplastic lesions, yet it cannot differentiate neoplastic from
non neoplastic thyroid lesions.
Our results showed that female sex, and patients’
age < 45 years showed signiﬁcantly higher CD44v6 expression
in malignant compared to non-malignant cases, yet, this statis-
tical signiﬁcance was also not maintained when cases were clas-
siﬁed as neoplatic and non-neoplastic.
Within the malignant group, and in agreement with oth-
ers,25 CD44v6 expression was higher in PTC compared to
FTC, yet, this difference did not reach statistical signiﬁcance.
The prevalance of CD44v6 in PTC was previously suggested
to be due to differences in the genetic background of both tu-
mors.25 However, when compared to non-malignant lesions,
PTC revealed signiﬁcantly higher CD44v6 overexpression,
which may support the suggestion that CD44 immunoreactiv-
ity may be of value in conﬁrming the diagnosis of borderline
ﬁne-needle aspirates, as stated previously by Ross et al.20
and Pazaitou-Panayiotou et al.26
CD44v6 overexpression did not associate with the PTC
subtype. Also, tumor size failed to relate signiﬁcantly with
CD44v6 expression when comparing the subtypes of PTC.
However, female sex, patients’ age < 45 years and tumor size
ranging between 1 cm and 4 cm were associated with signiﬁ-
cantly higher levels of positive CD44v6 immunostaining in
PTC compared to non-malignant lesions. Similarly, Hamam
et al.27 reported that CD44v6 expression was signiﬁcantly
higher in younger than older patients, although, others re-
ported absence of association between CD44 immunopositivi-
ty and tumor size, patients’ age and sex.24,28,29
Papillary thyroid carcinoma is considered to be an indolent
form of cancer with an excellent prognosis, yet occasional
cases may behave in an aggressive manner.20,30 CD44 was
implicated to facilitate lymph node metastasis,20,31,32 yet
whether its expression in PTC, predicts disease progression,
and explains the propensity for this tumor to involve regional
lymph nodes is still under investigation.20
In this study, we were not able to fully investigate the role
of CD44v6 overexpression in PTC in the development of regio-
nal nodal metastasis. However, it was noted that the nodal
metastatic deposits of PTC failed to stimulate a signiﬁcant
lymphoid tissue reaction. This may result from the lympho-
cyte-like surface molecule expression that appears as a charac-
teristic of this tumor.20 Thus, further evaluation of CD44
expression in thyroid papillary carcinoma as a predictive mar-
ker for cervical nodal metastasis is strongly warranted.
Figure 4 (A) Follicular thyroid carcinoma, score 3, (CD44v6, ·200).The inset highlights the membranous staining (CD44v6, ·1000). (B)
Hu¨rthle cell carcinoma, score 3 (CD44v6, ·200), and the inset demonstrates the positive membrane staining (CD44v6, ·400).
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ied FTCs. Conversely, the three studied follicular adenomas
were CD44v6 negative. This goes in agreement with studies
that reported FTC to highly express CD44v6 compared to fol-
licular adenoma19,33 to the degree that they proposed that
CD44v6 might be a useful diagnostic tool for the differentia-
tion of FTC from follicular adenoma on thyroid ﬁne needle
aspiration. CD44 negativity in adenomas may be due to the
shedding of ectodomain34–36 or failure of recognition of the
receptor by the antibody due to post-translational changes
which alter the 3-dimensional conformation of the protein.28,37
In our study, CD44v6 negativity in adenoma cases goes
with previous reports that the expression of CD44v6 in follic-
ular adenomas ranges from 0% to 58.33%.21,24,29,33,38 We re-
port CD44v6 immunopositivity in 50% of multinodular
goiters, which is within the expression range reported by some
studies.4,7,22,38 Conversely, other researchers reported the ab-
sence of CD44 in multinodular goiter.20,21 As regards Hashim-
oto’s thyroiditis we report a CD44v6 expression rate that goesin agreement with others,7,22 and the relative relation between
Hashimoto thyroiditis and thyroid cancer may explain the
CD44 expression in the former.7 Conversely, Chieng et al.21 re-
ported that CD44v6 was not expressed in this lesion.
Similar to others,4,20,22,33,38 we report that the background
non-neoplastic thyroid tissue was CD44v6 negative in all cases
of both groups except for four cases of PTCs that revealed
moderate to weak CD44v6 immunostaining of the background
thyroid parenchyma. Conversely, background positivity was
explained by Ermak et al.4 and Mackay et al.39 by the release
of soluble factors from the tumor resulting in the expression of
CD44v6 in the normal adjacent thyroid tissue.
Most of the differentiated thyroid carcinomas (PTC and
FTC), in opposition to non-malignant thyroid lesions and nor-
mal thyroid follicular cells, overexpress CD44v6. This suggests
that deregulated expression of this adhesion molecule may play
a role in the pathogenesis and better biological behavior of dif-
ferentiated thyroid carcinomas. The usefulness of CD44 in
conﬁrming the diagnosis of PTC on borderline ﬁne needle aspi-
Figure 5 (A) Microfollicular adenoma negative for CD44v6 (CD44v6, ·200). The inset demonstrates negative staining of neoplastic
thyroid follicles, (CD44v6, ·1000). (B) Hu¨rthle cell adenoma, negative for CD44v6, (·200), with absence of the membramous staining in
neoplastic cells seen in the inset, (CD44v6, ·1000). (C) Multinodular goiter, score 2, (CD44v6, ·200). (D) Hashimoto’s thyroiditis,
showing focal moderate to strong immunoreactivity of the Hu¨rthle cells, score 1 (CD44v6·100), that is highlighted in the inset (CD44v6,
·400).
248 S.M. El-Gendi et al.rates, and its utility in predicting cervical nodal metastatsis
needs to be investigated on a larger number of cases. Also,
evaluating the role of CD44v6 in differentiating follicular ade-
noma from follicular carcinoma in routine surgical pathology
should be investigated.
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